This B-Luc Hep 3B plus cell line expresses firefly luciferase as a marker of Hep 3B cells. Luminescence can be observed in B-Luc Hep 3B plus cells.

Gene targeting strategy for B-Luc Hep 3B plus cells. The exogenous promoter and luciferase were inserted into the AAVS1 locus in B-Luc Hep 3B plus.

Luminescence signal intensity of B-Luc Hep 3B plus cells. Luminescence intensity was measured using the Bright-Glo^TM luciferase Assay. B-Luc Hep 3B plus cells have a strong luminescence signal. The 1-A06 clone of B-Luc Hep 3B plus cells can be used in vivo experiments.

Subcutaneous homograft tumor growth of B-Luc Hep 3B plus cells. B-Luc Hep 3B plus cells (8x10⁶) and wild-type Hep 3B cells (8x10⁶) were subcutaneously implanted into B-NDG mice (female, 5-week-old, n=4). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-Luc Hep 3B plus cells were able to establish tumors in vivo and can be used for efficacy studies.

Tumor growth and in vivo imaging of B-Luc Hep 3B plus cells. B-Luc Hep 3B plus cells (8x10⁶) were subcutaneously implanted into the wild-type B-NDG mice. Signal intensity and body weight were measured twice a week. (A) Imaging was performed twice a week. (B) Body weight (Mean ± SEM). B-Luc Hep 3B plus cells can be used for in vivo efficacy evaluation.